- Acumen Powered by Robins Kaplan LLP®
- Affirmative Recovery
- American Indian Law and Policy
- Antitrust and Trade Regulation
- Appellate Advocacy and Guidance
- Business Litigation
- Civil Rights and Police Misconduct
- Class Action Litigation
- Commercial/Project Finance and Real Estate
- Corporate Governance and Special Situations
- Corporate Restructuring and Bankruptcy
- Domestic and International Arbitration
- Entertainment and Media Litigation
- Health Care Litigation
- Insurance and Catastrophic Loss
- Intellectual Property and Technology Litigation
- Mass Tort Attorneys
- Medical Malpractice Attorneys
- Personal Injury Attorneys
- Telecommunications Litigation and Arbitration
- Wealth Planning, Administration, and Fiduciary Disputes
Acumen Powered by Robins Kaplan LLP®
Ediscovery, Applied Science and Economics, and Litigation Support Solutions
-
April 29, 2024Robins Kaplan Mourns Death of New York Associate Waleed Abbasi
-
April 29, 2024Robins Kaplan Secures $7.75 Million Verdict in Aerosol Dust Remover Abuse Case
-
April 23, 2024David Martinez Recognized Among Top 100 Lawyers in Los Angeles by LA Business Journal
-
May 9, 2024Property Insurance Claims Group 2024 Conference
-
May 20, 2024The Present and Future of DEI
-
May 23, 202414th Annual Disability Justice Seminar
-
April 30, 2024A World Without Non-Competes: Protecting Confidential Information and Trade Secrets Following the FTC's Ban
-
First QuarterGENERICally Speaking: A Hatch-Waxman Litigation Bulletin
-
March 2024e-Commerce: Pitfalls and Protections
-
September 16, 2022Uber Company Systems Compromised by Widespread Cyber Hack
-
September 15, 2022US Averts Rail Workers Strike With Last-Minute Tentative Deal
-
September 14, 2022Hotter-Than-Expected August Inflation Prompts Massive Wall Street Selloff
Find additional firm contact information for press inquiries.
Find resources to help navigate legal and business complexities.
Read our attorneys' take on the latest news and trends in the legal and business industries.
New ANDA Cases
Summer 2016
Case Name | Date Filed | Judge | Drug | Patent No(s). |
---|---|---|---|---|
Alembic Pharms. Ltd. v. Daiichi Sankyo Co., Ltd., 16-3956 (N.D. Ill.) | Apr. 1, 2016 | Hon. John Z. Lee | Benicar® (olmesartan medoxomil tablets) | 6,878,703 |
Merck Sharp & Dohme Corp. v. Roxane Labs., Inc., 16-0285 (S.D. Ohio) | Apr. 1, 2016 | Hon. James L. Graham | Noxafil® (posaconazole oral suspension) |
5,661,151
6,958,337
|
Warner Chilcott (US), LLC v. Zydus Pharms. (USA) Inc., 16-0323 (E.D. Tex.) | Apr. 1, 2016 | Hon. Rodney Gilstrap | Delzicol® (mesalamine delayed-release capsules) | 6,649,180 |
Lupin Ltd. v. Horizon Therapeutics, Inc., IPR2016-00829 (PTAB) | Apr. 1, 2016 | N/A | Ravicti® (glycerol phenylbutyrate oral solution) | 9.095.559 |
Millennium Pharms., Inc. v. Actavis LLC, 16-0223 (D. Del.) | Apr. 4, 2016 | Hon. Gregory M. Sleet | Velcade® (bortezomib for injection) | 6,713,446 |
Javelin Pharms., Inc. v. Mylan Labs. Ltd., 16-0224 (D. Del.) | Apr. 4, 2016 | Hon. Leonard P. Stark | Dyloject® (diclofenac sodium for injection) |
6,407,079
8,946,292
|
Abraxis Bioscience, LLC v. Actavis LLC, 16-1925 (D.N.J.) | Apr. 6, 2016 | Hon. John Michael Vazquez | Abraxane® (albumin-bound paclitaxel for injection) |
7,820,788
7,923,536
8,138,229
8,853,260
|
Javelin Pharms., Inc. v. Mylan Labs. Ltd., 16-0059 (N.D.W.V.) | Apr. 6, 2016 | Hon. Irene M. Keeley | Dyloject® (diclofenac sodium for injection) |
6,407,079
8,946,292
|
Acura Pharms., Inc. v. Purdue Pharma L.P., IPR2016-00849 (PTAB) | Apr. 6, 2016 | N/A | OxyContin® (oxycodone tablets) | 8,389,007 |
Fresenius Kabi USA, LLC v. Maia Pharms., Inc., 16-0237 (D. Del.) | Apr. 7, 2016 | Hon. Gregory M. Sleet | Levothyroxine Sodium (levothyroxine sodium for injection) |
9,006,289
9,168,238
9,168,239
|
Alcon Research, Ltd. v. Watson Labs., Inc., 16-0238 (D. Del.) | Apr. 7, 2016 | Hon. Richard G. Andrews | Izba® (travoprost ophthalmic solution) |
8,178,582
8,722,735
8,754,123
9,144,561
|
AstraZeneca Pharms. LP v. InnoPharma Licensing LLC, 16-1962 (D.N.J.) | Apr. 7, 2016 | Hon. Renee Marie Bumb | Faslodex® (fulvestrant injection) |
6,774,122
7,456,160
8,329,680
8,466,139
|
Bayer Intellectual Property GMBH v. Micro Labs Ltd., 16-0242 (D. Del.) | Apr. 8, 2016 | Hon. Sue L. Robinson | Xarelto® (rivaroxaban tablets) |
7,585,860
7,592,339
|
Takeda Pharm. Co. Ltd. v. Teva Pharms. USA, Inc., 16-0246 (D. Del.) | Apr. 8, 2016 | Hon. Leonard P. Stark | Prevacid® SoluTab™ (lansoprazole delayed-release orally disintegrating tablets) |
6,328,994
7,431,942
7,875,292
7,399,485
|
Upsher-Smith Labs., Inc. v. Zydus Pharms. (USA) Inc., 16-0248 (D. Del.) | Apr. 8, 2016 | Hon. Sue L. Robinson | Qudexy® XR (topiramate extended-release capsules) |
8,652,527
8,889,190
9,101,545
|
Fresenius Kabi USA, LLC v. B. Braun Medical Inc., 16-0250 (D. Del.) | Apr. 11, 2016 | Hon. Richard G. Andrews | Diprivan® (propofol for injection) | 8,476,010 |
Allergan, Inc. v. Famy Care Ltd., 16-0401 (E.D. Tex.) | Apr. 12, 2016 | Hon. Rodney Gilstrap | Restasis® (cyclosporine ophthalmic emulsion) |
8,629,111
8,633,162
8,642,556
8,648,048
8,685,930
9,248,191
|
Takeda GMBH v. Torrent Pharma Inc., 16-1280 (D.N.J.) | Apr. 13, 2016 | Hon. Freda L. Wolfson | Daliresp® (roflumilast tablets) | 5,712,298 |
Galderma Labs., L.P. v. Akorn, Inc., 16-1012 (N.D. Tex.) | Apr. 14, 2016 | Hon. David C Godbey | Clobex® (clobetasol propionate spray) | 5,972,920 |
Forest Labs., LLC v. Apotex Corp., 16-0269 (D. Del.) | Apr. 15, 2016 | Hon. Gregory M. Sleet | Teflaro® (ceftaroline fosamil injection) | 6,417,175 |
Teva Pharms. USA, Inc. v. Biocon Ltd., 16-0278 (D. Del.) | Apr. 19, 2016 | Hon. Gregory M. Sleet | Copaxone® (glatiramer acetate injection) |
8,232,250
8,399,413
8,969,302
9,155,776
|
Sanofi-Aventis U.S. LLC v. Dr. Reddy's Labs., Inc., 16-2259 (D.N.J.) | Apr. 21, 2016 | Hon. Michael A. Shipp | Jevtana® Kit (cabazitaxel solution for infusion) | 5,847,170 |
Novartis AG v. Mylan Pharms. Inc., 16-0289 (D. Del.) | Apr. 22, 2016 | Hon. Leonard P. Stark | Gilenya® (fingolimod capsules) | 5,604,229 |
Senju Pharm. Co., Ltd. v. Hi-tech Pharmacal Co., Inc., 16-2270 (D.N.J.) | Apr. 22, 2016 | Hon. Jerome B. Simandle | Prolensa® (bromfenac ophthalmic solution) |
8,129,431
8,669,290
8,754,131
8,871,813
8,927,606
9,144,609
|
Par Pharm., Inc. v. Luitpold Pharms., Inc., 16-2290 (D.N.J.) | Apr. 22, 2016 | Hon. William H. Walls | Adrenalin® (epinephrine injection) |
9,119,876
9,295,657
|
Par Pharm., Inc. v. Luitpold Pharms., Inc., 16-1999 (E.D.N.Y.) | Apr. 22, 2016 | Hon. Ann M Donnelly | Adrenalin® (epinephrine injection) |
9,119,876
9,295,657
|
Galderma Labs., L.P. v. Tolmar Inc., 16-1099 (N.D. Tex.) | Apr. 22, 2016 | Hon. David C Godbey | Epiduo® (adapalene and benzoyl peroxide gel) |
8,071,644
8,080,537
8,129,362
8,445,543
8,809,305
|
Amneal Pharms. LLC v. GlaxoSmithKline LLC, 16-0300 (D. Del.) | Apr. 25, 2016 | Hon. Sue L. Robinson | Lamictal XR® (lamotrigine extended-release tablets) |
8,637,512
9,144,547
|
Boehringer Ingelheim Pharma GMBH & Co. KG v. Hetero USA, Inc., 16-2356 (D.N.J.) | Apr. 26, 2016 | Hon. Mary L. Cooper | Pradaxa® (dabigatran etexilate mesylate capsules) | 6,087,380 |
Boehringer Ingelheim Pharms. Inc. v. Dr. Reddy's Labs., Ltd., 16-2394 (D.N.J.) | Apr. 28, 2016 | Hon. Peter G. Sheridan |
Tradjenta® (linagliptin tablets)
Jentadueto® (linagliptin / metformin hydrochloride tablets)
|
9,173,859 |
AstraZeneca AB v. Hetero USA Inc., 16-2442 (D.N.J.) | Apr. 29, 2016 | Hon. Mary L. Cooper | Nexium® 24HR (esomeprazole magnesium delayed-release capsules) |
6,369,085
7,411,070
|
Aurobindo Pharms. Ltd. v. Daiichi Sankyo, Inc., 16-4876 (N.D. Ill.) | May 2, 2016 | Hon. Rebecca R. Pallmeyer |
Benicar® (olmesartan medoxomil tablets)
Benicar HZT® (olmesartan medoxomil / hydrochlorothiazide tablets)
|
6,878,703 |
BTG International Ltd. v. Amerigen Pharms., Inc., 16-2449 (D.N.J.) | May 2, 2016 | Hon. Kevin McNulty | Zytiga® (abiraterone acetate tablets) | 8,822,438 |
Otsuka Pharm. Co., Ltd. v. Zhejiang Huahai Pharm. Co., Ltd., 16-2475 (D.N.J.) | May 2, 2016 | Hon. Jerome B. Simandle, | Abilify® (aripiprazole tablets) | 8,759,350 |
Otsuka Pharm. Co., Ltd. v. Zhejiang Huahai Pharm. Co., Ltd., 16-2476 (D.N.J.) | May 2, 2016 | Hon. Jerome B. Simandle | Abilify® (aripiprazole tablets) | 9,089,567 |
Endo Pharms. Inc. v. Impax Labs., Inc., 16-2526 (D.N.J.) | May 4, 2016 | Hon. Jose L. Linares | Opana® ER (extended-release oxymorphone hydrochloride) |
8,309,122
8,329,216
8,808,737
|
Leo Pharma A/S v. Actavis Labs. UT, Inc., 16-0333 (D. Del.) | May 6, 2016 | Hon. Sue L. Robinson | Picato® (ingenol mebutate gel) |
7,410,656
8,278,292
8,372,827
8,372,828
8,377,919
8,536,163
8,716,271
8,735,375
|
AstraZeneca LP v. Watson Labs., Inc., 16-0338 | May 9, 2016 | Hon. Richard G. Andrews | Brilinta® (ticagrelor tablets) |
6,525,060
7,250,419
7,265,124
|
Breckenridge Pharm., Inc. v. Novartis AG, IPR2016-01023 (PTAB) | May 10, 2016 | N/A |
Zortress® (everolimus tablets)
Afinitor® (everolimus tablets)
Afinitor® Disperz (everolimus oral suspension)
|
5,665,772 |
Rhodes Pharms. L.P. v. Actavis, Inc., 16-2667 (D.N.J.) | May 11, 2016 | Hon. William H. Walls | Aptensio XR® (methylphenidate hydrochloride extended-release capsules) |
6,419,960
7,083,808
7,247,318
7,438,930
8,580,310
9,066,869
|
Mylan Institutional LLC v. Aurobindo Pharma Ltd., 16-0491 (E.D. Tex.) | May 11, 2016 | Hon. Robert W. Schroeder, III | Isosulfan blue (isosulfan blue) |
7,662,992
8,969,616
|
Amneal Pharma. LLC v. Purdue Pharma L.P., IPR2016-01027 (PTAB) | May 11, 2016 | N/A | OxyContin® (oxycodone hydrochloride extended-release tablets) | 9,060,976 |
Amneal Pharma. LLC v. Purdue Pharma L.P., IPR2016-01028 (PTAB) | May 11, 2016 | N/A | OxyContin® (oxycodone hydrochloride extended-release tablets) | 9,060,976 |
Wockhardt Bio AG v. AstraZeneca AB, IPR2016-01029 (PTAB) | May 11, 2016 | N/A |
Kombiglyze® XR (metformin hydrochloride / saxagliptin hydrochloride extended-release tablets)
Onglyza® (saxagliptin hydrochloride tablets)
|
RE44,186 |
Mylan Pharms Inc. v. Shire Labs., Inc., IPR2016-01033 (PTAB) | May 12, 2016 | N/A | Adderall® XR (amphetamine aspartate / amphetamine sulfate / dextroamphetamine saccharate / dextroamphetamine sulfate extended-release capsules) | RE42,096 |
Santen Pharm. Co., Ltd. v. Micro Labs Ltd., 16-0353 (D. Del.) | May 13, 2016 | Hon. Gregory M. Sleet | Zioptan® (tafluprost ophthalmic solution) | 5,886,035 |
Santen Pharm. Co., Ltd. v. Sandoz Inc., 16-0354 (D. Del.) | May 13, 2016 | Hon. Gregory M. Sleet | Zioptan® (tafluprost ophthalmic solution) | 5,886,035 |
Par Pharm., Inc. v. Novartis AG, IPR2016-01059 (PTAB) | May 17, 2016 | N/A |
Zortress® (everolimus tablets)
Afinitor® (everolimus tablets)
Afinitor® Disperz (everolimus oral suspension)
|
5,665,772 |
ApoPharma Inc. v. Taro Pharm. Indus., Ltd., 16-0528 (E.D. Tex.) | May 18, 2016 | Hon. Robert W. Schroeder, III | Ferriprox® (deferiprone tablets) | 7,049,328 |
Novartis AG v. Mylan Pharms. Inc., 16-0093 (N.D.W.V.) | May 18, 2016 | Hon. Irene M. Keeley | Gilenya® (fingolimod capsules) | 5,604,229 |
Forest Labs., LLC v. Accord Healthcare, Inc., 16-0375 (D. Del.) | May 20, 2016 | Hon. Leonard P. Stark | Namzaric® (memantine hydrochloride / donepezil hydrochloride extended-release capsules) |
8,039,009
8,058,291
8,168,209
8,173,708
8,283,379
8,293,794
8,329,752
8,338,485
8,338,486
8,362,085
8,580,858
8,598,233
|
Lotus Pharm. Co., Ltd. v. GlaxoSmithKline LLC, 16-0377 (D. Del.) | May 20, 2016 | Hon. Gregory M. Sleet | Lamictal XR® (lamotrigine extended-release tablets) |
8,637,512
9,144,547
|
Mylan Pharms., Inc. v. Research Corp. Technologies, Inc., IPR2016-01101 (PTAB) | May 25, 2016 | N/A | Vimpat® (lacosamide) | RE38,551 |
Allergan, Inc. v. Somerset Therapeutics, LLC, 16-0392 (D. Del.) | May 26, 2016 | Hon. Gregory M. Sleet | Lastacaft® (alcaftadine ophthalmic solution) | 8,664,215 |
Roxane Labs., Inc. v. Novartis AG, IPR2016-01102 (PTAB) | May 26, 2016 | N/A |
Zortress® (everolimus tablets)
Afinitor® (everolimus tablets)
Afinitor® Disperz (everolimus oral suspension)
|
5,665,772 |
Breckenridge Pharm., Inc. v. Novartis AG, IPR2016-01103 (PTAB) | May 26, 2016 | N/A |
Zortress® (everolimus tablets)
Afinitor® (everolimus tablets)
Afinitor® Disperz (everolimus oral suspension)
|
5,665,772 |
Alvogen Pine Brook LLC v. Noven Pharms., Inc., 16-0395 | May 27, 2016 | Hon. Leonard P. Stark | Minivelle® (estradiol extended-release film) |
6,841,716
8,231,906
|
Orexo AB v. Actavis Elizabeth LLC, 16-0397 (D. Del.) | May 27, 2016 | Hon. Sue L. Robinson | Zubsolv® (buprenorphine hydrochloride / naloxone hydrochloride sublingual tablets) | 9,259,421 |
AbbVie Inc. v. Amneal Pharms., LLC, 16-0398 (D. Del.) | May 27, 2016 | Hon. Richard G. Andrews | Norvir® (ritonavir tablets) |
7,148,359
7,364,752
|
Luye Pharma Group Ltd. v. Alkermes Pharma Ireland Ltd, IPR2016-01095 (PTAB) | May 31, 2016 | N/A |
Bydureon® (exenatide synthetic extended-release suspension)
Vivitrol® (naltrexone extended-release suspension)
Risperdal® (risperidone for injection)
|
6,667,061 |
Luye Pharma Group Ltd. v. Alkermes Pharma Ireland Ltd, IPR2016-01096 (PTAB) | May 31, 2016 | N/A |
Bydureon® (exenatide synthetic extended-release suspension)
Vivitrol® (naltrexone extended-release suspension)
Risperdal® (risperidone for injection)
|
6,667,061 |
Dr. Reddyy's Labs., Ltd v. MonoSol RX, LLC, IPR2016-01111 (PTAB) | May 31, 2016 | N/A | Suboxone® (buprenorphine hydrochloride / naloxone hydrochloride film) | 8,603,514 |
Dr. Reddyy's Labs., Ltd v. MonoSol RX, LLC, IPR2016-01112 (PTAB) | May 31, 2016 | N/A | Suboxone® (buprenorphine hydrochloride / naloxone hydrochloride film) | 8,017,150 |
Dr. Reddyy's Labs., Ltd v. Indivior UK Limited f/k/a RB Pharms. Ltd., IPR2016-01113 (PTAB) | May 31, 2016 | N/A | Suboxone® (buprenorphine hydrochloride / naloxone hydrochloride film) | 8,475,832 |
Sun Pharm. Indus., Ltd. v. AstraZeneca AB, IPR2016-01104 (PTAB) | June 1, 2016 | N/A |
Kombiglyze® XR (metformin hydrochloride / saxagliptin hydrochloride extended-release tablets)
Onglyza® (saxagliptin hydrochloride tablets)
|
RE44,186 |
Teva Pharms. USA, Inc. v. AstraZeneca AB, IPR2016-01122 (PTAB) | June 1, 2016 | N/A |
Kombiglyze® XR (metformin hydrochloride / saxagliptin hydrochloride extended-release tablets)
Onglyza® (saxagliptin hydrochloride tablets)
|
RE44,186 |
Aurobindo Pharma U.S.A., Inc. v. AstraZeneca AB, IPR2016-01117 (PTAB) | June 2, 2016 | N/A |
Kombiglyze® XR (metformin hydrochloride / saxagliptin hydrochloride extended-release tablets)
Onglyza® (saxagliptin hydrochloride tablets)
|
RE44,186 |
Mylan Pharms. Inc. v. Allergan, Inc., IPR2016-01127 (PTAB) | June 3, 2016 | N/A | Restasis® (cyclosporine ophthalmic emulsion) | 8,685,930 |
Mylan Pharms. Inc. v. Allergan, Inc., IPR2016-01128 (PTAB) | June 3, 2016 | N/A | Restasis® (cyclosporine ophthalmic emulsion) | 8,629,111 |
Mylan Pharms. Inc. v. Allergan, Inc., IPR2016-01129 (PTAB) | June 3, 2016 | N/A | Restasis® (cyclosporine ophthalmic emulsion) | 8,642,556 |
Mylan Pharms. Inc. v. Allergan, Inc., IR2016-01130 (PTAB) | June 3, 2016 | N/A | Restasis® (cyclosporine ophthalmic emulsion) | 8,633,162 |
Mylan Pharms. Inc. v. Allergan, Inc., IPR2016-01131 (PTAB) | June 3, 2016 | N/A | Restasis® (cyclosporine ophthalmic emulsion) | 8,648,048 |
Mylan Pharms. Inc. v. Allergan, Inc., IPR2016-01132 (PTAB) | June 3, 2016 | N/A | Restasis® (cyclosporine ophthalmic emulsion) | 9,248,191 |
Mylan Pharms., Inc. v. Senju Pharm. Co., Ltd., IPR2016-01163 (PTAB) | June 8, 2016 | N/A | Bepreve® (bepotastine besilate ophthalmic solution) | 8,877,168 |
Aurobindo Pharma USA Inc. v. Apicore US LLC, 16-3358 (D.N.J.) | June 9, 2016 | Hon. Renee Marie Bumb | Isosulfan blue (isosulfan blue) |
7,662,992
8,969,616
9,353,050
|
Leo Pharma A/S v. Perrigo UK Finco Ltd. Partnership, 16-0430 (D. Del.) | June 10, 2016 | Hon. Sue L. Robinson | Picato® (ingenol mebutate gel) |
6,432,452
6,787,161
6,844,013
7,410,656
8,278,292
8,372,827
8,372,828
8,377,919
8,536,163
8,716,271
8,735,375
|
Novartis Pharms. Corp. v. Breckenridge Pharm., Inc., 16-0431 (D. Del.) | June 10, 2016 | Hon. Richard G. Andrews | Afinitor® (everolimus tablets) |
5,665,772
8,410,131
8,778,962
|
Purdue Pharma L. P. v. Collegium Pharm., Inc., 16-11091 (D. Mass.) | June 10, 2016 | Hon. F. Dennis Saylor, IV |
OxyContin® (oxycodone)
Xtampza ER™ (oxycodone)
|
9,155,717 |
UCB, Inc. v. Aurobindo Pharma Ltd., 16-0451 (D. Del.) | June 17, 2016 | Hon. Leonard P. Stark | Vimpat® (lacosamide) | RE38,551 |
UCB, Inc. v. Hetero USA Inc., 16-0452 (D. Del.) | June 17, 2016 | Hon. Leonard P. Stark | Vimpat® (lacosamide) | RE38,551 |
Shire Orphan Therapies LLC v. InnoPharma, Inc., 16-0456 (D. Del.) | June 17, 2016 | Hon. Gregory M. Sleet | Firazyr® (icatibant for injection) | 5,648,333 |
United Therapeutics Corp. v. Actavis Labs. FL, Inc., 16-3642 (D.N.J.) | June 17, 2016 | Hon. Peter G. Sheridan | Orenitram® (treprostinil extended-release tablets) |
7,417,070
7,544,713
8,252,839
8,349,892
8,410,169
8,497,393
9,050,311
8,747,897
9,278,901
|
Noven Pharms., Inc. v. Actavis Labs. UT, Inc., 16-0465 (D. Del.) | June 20, 2016 | Hon. Leonard P. Stark | Minivelle® (estradiol transdermal system) | 8,231,906 |
Eli Lilly and Co. v. Apotex Inc., 16-1512 (S.D. Ind.) | June 20, 2016 | Hon. William T. Lawrence | Axiron® (testosterone metered transdermal solution) |
8,419,307
8,177,449
8,435,944
8,807,861
8,993,520
9,180,194
9,289,586
|
Breckenridge Pharm., Inc. v. Research Corp. Technologies, Inc., IPR2016-01242 (PTAB) | June 21, 2016 | N/A | Vimpat® (lacosamide) | RE38,551 |
Eli Lilly and Co. v. Apotex Inc., 16-0475 (D. Del.) | June 22, 2016 | Hon. Leonard P. Stark | Axiron® (testosterone metered transdermal solution) |
8,419,307
8,177,449
8,435,944
8,807,861
8,993,520
9,180,194
9,289,586
|
Argentum Pharms. LLC v. Allergan, Inc., IPR2016-01232 (PTAB) | June 22, 2016 | N/A | Restasis® (cyclosporine ophthalmic emulsion) | 8,629,111 |
Alembic Pharms., Ltd.v. Research Corp. Technologies, Inc., IPR2016-01245 (PTAB) | June 22, 2016 | N/A | Vimpat® (lacosamide) | RE38,551 |
Gilead Sciences, Inc. v. Aurobindo Pharma Ltd., 16-3722 (D.N.J.) | June 23, 2016 | Hon. Renee Marie Bumb | Emtriva® (emtricitabine capsules) |
6,642,245
6,703,396
|
Mylan Pharms., Inc. v. Research Corp. Technologies, Inc., IPR2016-01248 (PTAB) | June 23, 2016 | N/A | Vimpat® (lacosamide) | RE38,551 |
BTG Int'l Ltd. v. Glenmark Pharms. Inc., USA, 16-3743 (D.N.J.) | June 24, 2016 | Hon. Kevin McNulty | Zytiga® (abiraterone acetate tablets) | 8,822,438 |
Apotex Inc. v. Osi Pharms., Inc., IPR2016-01284 (PTAB) | June 28, 2016 | N/A | Tarceva® (erlotinib hydrochloride tablets) | 6,900,221 |
Genzyme Corp. v. Zydus Pharms. (USA) Inc., 16-0540 (D. Del.) | June 29, 2016 | Hon. Gregory M. Sleet | Mozobil® (plerixafor for injection) |
7,897,590
6,987,102
|
Janssen Pharmaceutica N.V. v. Xellia Pharms ApS, 16-0554 (D. Del.) | June 29, 2016 | Hon. Leonard P. Stark | Sporanox® (voriconazole for injection) | 6,407,079 |
Genzyme Corp. v. Amneal Pharms. LLC, 16-3892 (D.N.J.) | June 29, 2016 | Hon. Stanley R. Chesler | Clolar® (clofarabine for injection) | 5,661,136 |
Mylan Pharms., Inc. v. AstraZeneca AB, IPR2016-01316 (PTAB) | June 29, 2016 | N/A | Faslodex® (fulvestrant injection) | 6,774,122 |
Argentum Pharms. LLC v. Janssen Oncology, Inc., IPR2016-01317 (PTAB) | June 29, 2016 | N/A | Zytiga® (abiraterone acetate tablets) | 8,822,438 |
Mylan Pharms., Inc. v. AstraZeneca AB, IPR2016-01324 (PTAB) | June 29, 2016 | N/A | Faslodex® (fulvestrant injection) | 7,456,160 |
Mylan Pharms., Inc. v. AstraZeneca AB, IPR2016-01325 (PTAB) | June 29, 2016 | N/A | Faslodex® (fulvestrant injection) | 8,329,680 |
Mylan Pharms., Inc. v. AstraZeneca AB, IPR2016-01326 (PTAB) | June 29, 2016 | N/A | Faslodex® (fulvestrant injection) | 8,466,139 |
Alcon Pharms. Ltd. v. Imprimis Pharms., Inc., 16-0563 (D. Del.) | June 30, 2016 | Hon. Sue L. Robinson | Vigamox® (moxifloxacin hydrochloride ophthalmic solution) |
6,716,830
7,671,070
|
Genzyme Corp. v. Zydus Pharms. (USA) Inc., 16-3905 (D.N.J.) | June 30, 2016 | Hon. Renee Marie Bumb | Mozobil® (plerixafor for injection) |
7,897,590
6,987,102
|
Horizon Therapeutics, Inc. v. Par Pharm., Inc., 16-3910 (D.N.J.) | June 30, 2016 | Hon. Robert B. Kugler | Ravicti® (glycerol phenylbutyrate oral solution) |
9,095,559
9,254,278
9,326,966
|
Mylan Pharms., Inc. v. Janssen Oncology, Inc., IPR2016-01332 (PTAB) | June 30, 2016 | N/A | Zytiga® (abiraterone acetate tablets) | 8,822,438 |
Wockhardt Bio AG v. Eli Lilly and Co., IPR2016-01335 (PTAB) | June 30, 2016 | N/A | Alimta® (pemetrexed disodium for injection) | 7,772,209 |
Wockhardt Bio AG v. Eli Lilly and Co., IPR2016-01337 (PTAB) | June 30, 2016 | N/A | Alimta® (pemetrexed disodium for injection) | 7,772,209 |
GENERICally Speaking Summer 2016
Related Publications
First Quarter
GENERICally Speaking: A Hatch-Waxman Litigation Bulletin
Oren Langer, Christopher Pinahs, Emily Tremblay, and Christine May
March 25, 2024
Endo Ventures Unlimited Co. v. Nexus Pharms. Inc.
GENERICally Speaking Hatch Waxman Bulletin
March 22, 2024
Mallinckrodt plc v. Airgas Therapeutics LLC
GENERICally Speaking Hatch Waxman Bulletin
March 8, 2024
UCB, Inc. v. Mylan Techs. Inc.
GENERICally Speaking Hatch Waxman Bulletin
March 5, 2024
Genentech, Inc. v. Sandoz, Inc.
GENERICally Speaking Hatch Waxman Bulletin
Related News
October 14, 2022
September 9, 2022
Back to Top
Any information that you send us in an e-mail message should not be confidential or otherwise privileged information. Sending us an e-mail message will not make you a client of Robins Kaplan LLP. We do not accept representation until we have had an opportunity to evaluate your matter, including but not limited to an ethical evaluation of whether we are in a conflict position to represent you. Accordingly, the information you provide to us in an e-mail should not be information for which you would have an expectation of confidentiality.
If you are interested in having us represent you, you should call us so we can determine whether the matter is one for which we are willing or able to accept professional responsibility. We will not make this determination by e-mail communication. The telephone numbers and addresses for our offices are listed on this page. We reserve the right to decline any representation. We may be required to decline representation if it would create a conflict of interest with our other clients.
By accepting these terms, you are confirming that you have read and understood this important notice.
If you are interested in having us represent you, you should call us so we can determine whether the matter is one for which we are willing or able to accept professional responsibility. We will not make this determination by e-mail communication. The telephone numbers and addresses for our offices are listed on this page. We reserve the right to decline any representation. We may be required to decline representation if it would create a conflict of interest with our other clients.
By accepting these terms, you are confirming that you have read and understood this important notice.